NCT06901726View on ClinicalTrials.gov

Open, Randomized Crossover Study on PK, PD, Biopotency, and Bioavailability of Insulin Capsules in Healthy Chinese Males

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

April 24, 2025

Study Completion Date

June 1, 2025

Conditions
Diabetes Mellitus
Interventions
DRUG

Human insulin enteric coated capsules in dose 32mg

Single oral administration of human insulin enteric coated capsules in dose 32mg (16 mg per capsule, two capsules).

DRUG

Human Insulin Injection in dose 5IU

Single subcutaneous administration of Human Insulin Injection in dose 5IU.

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER